论文部分内容阅读
为了寻找适于多肽分子吸收,免疫学上“有效”、“安全”,且服用方便的口服制剂,用W/O/W型乳化挥发法制备胸腺肽聚乳酸微球,正交实验方法优化了制备工艺.通过差热分析证明载药微球已较好形成,Lowry法测定药物的含量,计算微球的载药量、包封率及体外释药量.结果表明,所得微球平均粒径为13.8μm,平均包封率为80.7%,前12h的体外释药符合Higuchi方程,T1/2=295min,在25℃和40℃分别放置90d,微球的粒径分布和剩余药量无显著变化.微球的载药量和包封率符合要求,释药半衰期长,具有良好的应用前景.
In order to find an oral preparation that is suitable for absorption, immunological activity, safety and easy to take, the thymosin polylactic acid microspheres were prepared by W / O / W emulsification volatilization. The orthogonal experimental method was optimized The microstructure of the microspheres was characterized by differential thermal analysis (DTA), and the drug content was determined by Lowry method.The drug loading, entrapment efficiency and drug release of the microspheres were calculated by the differential thermal analysis.The results showed that the average particle size 13.8μm, the average entrapment efficiency was 80.7%. The in vitro drug release in the first 12h was in accordance with the Higuchi equation, T1 / 2 = 295min. After being stored at 25 ℃ and 40 ℃ for 90 d, the particle size distribution and the remaining dose did not change significantly The drug loading and entrapment efficiency of microspheres meet the requirements, and the half-life of drug release is long, which has a good prospect of application.